The Billion-Dollar Blood Gold Rush: Plasma Fraction Market Size to Exceed USD 62 Billion by 2032 as Life-Saving Therapies Face Unprecedented Demand
Imagine a single liter of straw-colored liquid — human blood plasma — containing the raw ingredients for dozens of life-saving medications that treat conditions ranging from hemophilia to primary immune deficiency, from severe burns to traumatic shock. This precious biological resource, donated by millions of volunteers worldwide, undergoes a complex industrial process called fractionation that separates, purifies, and transforms it into therapeutic products that millions of patients depend on for survival. Unlike synthetic pharmaceuticals that can be manufactured in chemical reactors, plasma-derived therapies begin with a human biological starting material that cannot be synthesized, cannot be stockpiled indefinitely, and depends entirely on the willingness of donors to contribute. This unique supply-demand dynamic creates one of the most strategically compelling markets in global healthcare. This market analysis reveals how the global plasma fraction market, currently valued at USD 37,710 million, is projected to reach an impressive USD 62,130 million by 2032, growing at a robust CAGR of 7.5% as rising disease prevalence, expanding clinical applications, and emerging market demand converge to create sustained growth.
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Plasma Fraction – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Plasma Fraction market, including market size, share, demand, industry development status, and forecasts for the next few years.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6011221/plasma-fraction
Market Analysis: A USD 37.7 Billion Baseline Driven by Biological Necessity
The data tells an extraordinary growth story that pharmaceutical executives, healthcare investors, and blood products industry leaders need to understand right now. The global market for Plasma Fraction was estimated to be worth USD 37,710 million in 2025 and is projected to reach USD 62,130 million, growing at a CAGR of 7.5% from 2026 to 2032. This market size expansion adds approximately USD 24,420 million in new value over the forecast period. Human blood plasma is nature’s raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called Plasma Fraction. The market encompasses critical therapeutic products including Immune Globulin, Coagulation Factor, Albumin, and other plasma-derived therapies.
What makes this market analysis particularly compelling is the supply-demand asymmetry that characterizes the plasma fraction industry. Unlike conventional pharmaceuticals where manufacturing capacity can be scaled through capital investment, plasma-derived therapy production is fundamentally constrained by plasma collection volumes, which depend on donor availability, regulatory frameworks governing plasma donation, and the physical limitation that plasma donors can contribute a maximum of approximately twice per week with mandatory health screening at each donation.
Understanding Plasma Fraction Technology: From Human Donation to Life-Saving Therapy
Plasma fractionation is the industrial-scale process of separating human blood plasma into its therapeutic protein components. The process begins with the collection of source plasma through plasmapheresis, where whole blood is drawn, plasma is separated, and red blood cells are returned to the donor. The collected plasma undergoes a multi-stage fractionation process, typically based on the Cohn method or chromatographic techniques, that precipitates and purifies specific proteins based on their physicochemical properties.
The classification of Plasma Fraction includes Immune Globulin, Coagulation Factor, Albumin, and Other products. In 2023, Immune Globulin accounted for a share of 51% in the global Plasma Fraction market, making it the dominant product category. Immunoglobulins are increasingly used in the treatment of a wide range of diseases, including primary and secondary immune deficiencies, chronic inflammatory demyelinating polyneuropathy, and numerous autoimmune conditions. The growing clinical application breadth of immunoglobulin therapy — with new indications being approved regularly — drives sustained demand growth that consistently outpaces supply expansion.
Coagulation factors represent the second-largest product category, serving patients with hemophilia A and B, von Willebrand disease, and other bleeding disorders. The evolution from plasma-derived factor concentrates to recombinant factors and now extended half-life products and gene therapy alternatives creates competitive dynamics within the coagulation factor segment that influence plasma-derived product demand trajectories. Albumin, the most abundant protein in human plasma, serves critical therapeutic roles in volume resuscitation for shock and burns, paracentesis for liver disease, and as a stabilizer in pharmaceutical formulations.
Market Drivers: Disease Prevalence, Aging Populations, and Expanding Indications
The market analysis identifies several powerful drivers propelling the plasma fraction industry forward. The rising prevalence of chronic diseases, such as immune deficiencies, hemophilia, and autoimmune disorders, has led to increased demand for plasma-derived products. The global aging population is more prone to chronic diseases and conditions requiring plasma-derived therapies, contributing substantially to market growth. Immunoglobulins are increasingly used in the treatment of a wide range of diseases, boosting the need for Plasma Fraction to produce these therapies — the expansion of immunoglobulin indications alone represents a multi-billion-dollar demand driver that shows no signs of saturation.
Rising healthcare expenditure and improved healthcare access in developing countries are driving demand for advanced medical treatments and plasma-derived products. As healthcare infrastructure expands in emerging economies across Asia-Pacific, Latin America, and the Middle East, previously undiagnosed and untreated patient populations gain access to plasma-derived therapies, creating new demand that will sustain market growth for decades. China, in particular, has emerged as an important market for Plasma Fraction products, with domestic manufacturers including RAAS, CBPO, Hualan Bio, Tiantan Bio, and others building collection infrastructure and fractionation capacity to serve the growing domestic patient population.
Market Challenges: Supply Constraints, Costs, and Regulatory Complexity
However, the plasma fraction market faces significant structural challenges. The high costs of plasma-derived products, resulting from the complex and time-consuming fractionation process, make these treatments less accessible, particularly in low-income regions. The availability of plasma for fractionation is often limited by low donation rates, regulatory restrictions, and the lengthy process of screening and collecting plasma, leading to persistent supply shortages that constrain market growth.
Plasma fractionation is subject to rigorous regulatory requirements to ensure safety and efficacy. Meeting these regulations can increase development costs and slow the introduction of new products to the market. The complex manufacturing process is technically challenging and requires significant investment in infrastructure, equipment, and skilled labor, posing substantial barriers for new entrants and smaller manufacturers. The COVID-19 pandemic demonstrated the vulnerability of plasma supply chains, leading to decreased numbers of blood donations and plasma collections that created raw material shortages with cascading effects on product availability.
Regional Market Dynamics and Competitive Landscape
North America is the largest consumption market, with a revenue market share nearly 40% in 2023, driven by high immunoglobulin utilization, well-established plasma collection infrastructure, and favorable regulatory and reimbursement frameworks. The United States is uniquely positioned as both the largest consumer and the largest collector of source plasma, supplying a substantial portion of the global plasma fractionation raw material. Following North America, Europe is the second largest consumption market with a revenue market share of 24%, characterized by both commercial and public-sector plasma fractionation operations.
The competitive landscape is dominated by global plasma fractionation leaders including Takeda, CSL (through CSL Behring), Grifols, Octapharma, Kedrion, LFB Group, Biotest, and BPL, alongside important regional manufacturers in China including RAAS, CBPO, Hualan Bio, Tiantan Bio, Shuanglin Bio, Boya Bio, Yuanda Shuyang, Weiguang Bio, Nanyue Bio, and KM Biologics in Japan. The application segmentation across Hospital, Retail Pharmacy, and Other channels reflects the diverse distribution pathways for plasma-derived therapies.
Industry Outlook: The Road to USD 62.1 Billion by 2032
The industry outlook through 2032 is exceptionally positive, supported by the essential nature of plasma-derived therapies, expanding clinical indications, and growing global access to treatment. The trajectory from USD 37,710 million to USD 62,130 million represents a market expansion grounded in the irreplaceable role of human plasma as the starting material for dozens of life-sustaining therapies. For plasma fractionation companies, the strategic imperatives include expanding plasma collection capacity, investing in manufacturing efficiency improvements, and building market presence in high-growth emerging markets where treatment penetration remains substantially below Western levels.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
